Related Experiment Videos
Involvement of transforming growth factor-beta and its receptors in the pathogenesis of diabetic nephrology
1Penn Center for Molecular Studies of Kidney Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA. ziyadeh@mail.med.upenn.edu
Kidney International. Supplement
|September 1, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A risk-based stochastic energy-water-carbon nexus analytical model to support provincial multi-system synergistic management - A case study of Shanxi, China.
The Science of the total environment·2024
[Diagnosis and treatment of five neonatal cerebral venous sinus thrombosis].
Zhonghua er ke za zhi = Chinese journal of pediatrics·2018
Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
Transplantation proceedings·2018
Mechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes.
American journal of physiology. Renal physiology·2015
Involvement of the transforming growth factor-β system in the pathogenesis of diabetic nephropathy.
Clinical and experimental nephrology·2014
Involvement of renal cytochromes P450 and arachidonic acid metabolites in diabetic nephropathy.
Journal of biological regulators and homeostatic agents·2013
Effect of kidney disease on glucose handling (including genetic defects).
Kidney international. Supplement·2011
Need for better diabetes treatment for improved renal outcome.
Kidney international. Supplement·2011
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
Kidney international. Supplement·2011
SGLT2 inhibitors: molecular design and potential differences in effect.
Kidney international. Supplement·2011
Glucose handling by the kidney.
Kidney international. Supplement·2011
Bone: from a reservoir of minerals to a regulator of energy metabolism.
Kidney international. Supplement·2011
Targeting Cancer-Associated Fibroblasts with Small-Molecule Inhibitors: Molecular Mechanisms and Therapeutic Potential.
Drug design, development and therapy·2026
EGFR-antibody-decorated cancer-cell-membrane-coated MOF nanoplatform enables targeted delivery of the STING agonist diABZI for pancreatic cancer immunotherapy.
International journal of pharmaceutics: X·2026
Targeting MAT2A-S-adenosylmethionine (SAM) Axis Attenuates DNA Damage Response and Cancer Stemness to Increase Platinum Sensitivity in Ovarian Cancer.
bioRxiv : the preprint server for biology·2026